Our Product

Meet the MYLeukaemia Therapy Guidance Chipset: an organ-on-chip (OoC) that recreates the bone-marrow niche to capture how each patient’s cells actually respond to available therapies turning trial-and-error into evidence-guided therapy selection in just 72h.

Discover our innovative marrow-avatar platform.

How it Works

During routine diagnostics, the M.D. collects +5 mL extra peripheral/BM aspirate. Same-day courier brings the sample to our central lab, where we isolate viable leukaemia cells & load them into the MYLeukaemia Therapy Guidance Chipset - our bioengineered human bone-marrow avatar.

We challenge the blood cancer cells with 5 clinically used regimens, quantify Leukaemia cell response vs. healthy counterparts tolerance, and produce a tumour-board-ready heatmap that ranks most effective therapeutic options & flags QC. The result complements cytogenetics, flow, PCR and NGS, turning one-size fits all approach/trial-and-error into evidence-guided therapy selection.

For decisions perfectly tailored to your patient unique blood cancer profile.

1

> 100,000 patient leukaemia cells are isolated and integrated in a sophisticated MYLeukaemia Organ-on-Chip Chipset

Isolate Live Cells from Patients’ Blood

2

3

Patient-personalized Bone Marrow Avatar

Functional Precision Oncology sensitivity Testing

Drug testing for clinically used regimens ID's patients’ funcional AML drivers & rank drug sensitivity by FC

Patient-derived blasts colonize a 3D, vascularised Organ-on-Chip, recreating the patient’s bone marrow Leukemic niche within 24h.

MYLeukaemia Therapy Guidance Chipset is an R&D-stage functional precision oncology service (RUO/IVDR-aware). Not CE-IVD. Not a diagnostic. Clinical use restricted to IRB/ethics-approved pilots.

What Makes Our MYLeukaemia Chipset Unique

Designed for clinician-ready therapy ranking between cycles: measured, not guessed, and timely.

72-hour decision support

Unmatched native marrow-like niche bioengineering for clinically relevant, context-aware drug-response readouts.

Human Bone-Marrow avatars

Functional precision (ex vivo)

Functionally tests patient cancer cells beforehand to complement Standard-of-Care diagnostics (cytogenetics, flow, PCR, NGS) for truly personalized therapy choices.

Minimal-burden sampling

Just +5 mL added to routine peripheral or BM draws; no extra procedure.

Clear heatmap, ranked therapy options, QC flags; available clinical trials; in a simple & concise PDF report

Tumour-board-ready outputs

Pilot-ready & IVDR-aware

TRL4 with MVP on multiple AML cell lines; 20-patient pilot next; CE-IVD horizon ~24-36 months.

CEO | Hugo Caires, PhD

Project Leader with +12 years of experience in Tissue Engineering, Cancer & Clinical Research in Leukaemia. +18 papers in top journals with +3000 citations.

CBSO | Hugo Prazeres, MBA, PhD

+30 papers in top journals, Co-founder of 3+ biotech companies, including Fetalix & BEAT Therapeutics. Consultant on CE marking and IVD Medical Devices.

COO | Diana Sousa, MSc

Pharmacist with +11 years of experience in sales, community healthcare & health economics, bridging clinical insight with real-world commercialization.

Complementary Expertise. One Founding Team.

Our trusted partners & supporters

From recognition on international stages to competitive grant funding and clinical alliances, MYLeukaemia has earned validation at every step. These achievements form the foundation for our next chapter: transforming personalised therapy selection for blood cancer patients.

+2

peer-reviewed articles published

+€60k

capital raised for R&D

+2

years of R&D in top institutions

Awards

Early validation. Execution mode on.

Follow us on LinkedIN

MYLeukaemia

24 September, 2025

We’re sharing APCL’s clear explainer on Leukaemias. We stand with patients, families, and clinicians - and with the science still ahead. At MYLeukaemia, our mission is to bring functional precision science closer to hospital decision-making, so more people get the right therapy, sooner.

MYLeukaemia

17 July, 2025

We made the top 7. 🧬
Out of many groundbreaking startups across Europe, MYLeukaemia Project is heading to the finals of the EP PerMed Venture Creator.

Still processing (...)

MYLeukaemia

13 May, 2025

He was in his 30s.
Same age as me.

I didn’t know his name.
I just knew his blood.

He was my first ever blood cancer case.
Intermediate risk. Good initial response.

Everything said it should work (...)